Skip to main content

Table 4 Procedure-level net budget impact

From: Economic impact of improving patient safety using Sugammadex for routine reversal of neuromuscular blockade in Spain

Block Depth At Reversal

Prior NMBA & Reversal Agent

Prior Scenario Drug Costs

Alternative Scenario (incl. sugammadex) Drug Costs

Total Cost Offsets From Clinical Events Avoided

Net Cost Savings

Moderate

Rocuronium + No reversal

€1.80

€53.14

€307.61

-€256.27

Moderate

Rocuronium + Neostigmine

€2.27

€53.14

€307.61

-€256.73

Deep

Rocuronium + No reversal

€1.80

€104.48

€307.61

-€204.93

 

Average per procedure using Sugammadex

€1.97

€59.76

€307.61

-€249.82

 

Average across all surgical procedures (regardless of sugammadex usage)

0.58

17.67

90.97

-73.88